S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
Farhad Ravandi,Stefan Faderl +1 more
TL;DR: Treatment of adult T-cell leukemia (ATL) remains difficult and Alemtuzumab with or without nucleoside analogs such as pentostatin may provide a role, but the associated immunosuppression is a concern in patients with viral-mediated disease.
Journal ArticleDOI
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Talha Badar,Damian R. Handisides,Juliana Benito,Mary Ann Richie,Gautam Borthakur,Elias Jabbour,Karine Harutyunyan,Sergej Konoplev,Stefan Faderl,Stew Kroll,Michael Andreeff,Tillman E. Pearce,Hagop M. Kantarjian,Jorge E. Cortes,Deborah A. Thomas,Marina Konopleva +15 more
TL;DR: Hypoxia markers HIF‐1α and CAIX were highly expressed in leukemic bone marrow and were significantly reduced after evofosfamide therapy, which has shown limited activity in heavily pretreated leukemia patients.
Journal ArticleDOI
At high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cells
Uri Rozovski,David Harris,Ping Li,Zhiming Liu,Ji Yuan Wu,Srdana Grgurevic,Stefan Faderl,Alessandra Ferrajoli,William G. Wierda,Matthew Martinez,Srdan Verstovsek,Michael J. Keating,Zeev Estrov +12 more
TL;DR: It is found that STAT3 binds with low affinity to the caspase-3 promoter, suggesting that at high levels, STAT3 activates proapoptotic mechanisms and induces apoptosis in CLL cells.
Journal ArticleDOI
Clofarabine in leukemia
TL;DR: Owing to its unique properties of biochemical modulation when used in combination with other established antileukemic drugs, mainly cytarabine, combination regimens containing clofarabine are being evaluated.
Journal ArticleDOI
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure
Uri Rozovski,Ohad Benjamini,Preetesh Jain,Philip A. Thompson,William G. Wierda,Susan O'Brien,Jan A. Burger,Alessandra Ferrajoli,Stefan Faderl,Elizabeth J. Shpall,Chitra Hosing,Issa F. Khouri,Richard E. Champlin,Michael J. Keating,Zeev Estrov +14 more
TL;DR: Patients with CLL in whom allogeneic SCT fails may have a response to and benefit from salvage therapies, and their prognosis is relatively good.